COMMUNIQUÉS West-GlobeNewswire

XBiotech annonce la conclusion du recrutement pour l'étude multicentrique de phase 2 d'évaluation de Bermekimab chez les patients atteints d'une dermatite atopique
05/10/2018
AUSTIN, Texas, 05 oct. 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui avoir terminé le recrutement pour son étude clinique ouverte de phase 2 consacrée à l'évaluation de l'administration [...]
KemPharm Announces Pricing of Public Offering of Common Stock
05/10/2018
CORALVILLE, Iowa, Oct. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the pricing of its [...]
Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
05/10/2018
SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) [...]
FSD Pharma Takes the Spotlight in CNBC's Cannabis Coverage -- CFN Media
05/10/2018
SEATTLE, Wash., Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces [...]
Medibio Provides Updated Company Presentation
05/10/2018
SYDNEY, Australia and MINNEAPOLIS, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Medibio Limited ( MEB or the Company )(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is pleased to release an updated company [...]
Chemesis Rolling Up High Value Cannabis Assets in United States -- CFN Media
05/10/2018
SEATTLE, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
VPR Brands Showcasing its GOLDLINE Hemp Brand at NACS Expo in Las Vegas
05/10/2018
FORT LAUDERDALE, FL, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- VPR Brands, LP (OTC PINK: VPRB), a market leader specializing in accessories and vaporizers for essential oils, cannabis concentrates and [...]
Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder
05/10/2018
-- Furthers the Company’s strategy to expand neuromuscular gene therapy franchise -- -- CMT is a group of hereditary, degenerative nerve diseases that in addition to causing extraordinary pain, can greatly impact [...]
Agritek Holdings, Inc. Announces First Approved Hospitality Model And Full Service Wellness Resort As Cannabis Approaches Legalization In Canada This Month
05/10/2018
LOS ANGELES, CA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Agritek Holdings, Inc. (OTCQB: AGTK) www.AgritekHoldings.com , a fully integrated, active real estate investor for the cannabis sector in the United [...]
Veritas Signs MOU with Leader in Puerto Rico’s Medicinal Cannabis Market
05/10/2018
VANCOUVER, B.C., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce along with the Institute for Medical Cannabis (the [...]
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants
05/10/2018
WALTHAM, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public [...]
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
05/10/2018
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, will present [...]
CTD Holdings Establishes Second Clinical Trial Site for US Phase I Clinical Study of Trappsol® Cyclo™ for Treatment of Niemann-Pick Disease Type C
05/10/2018
Patients to be Enrolled at Atlantic Health System’s Morristown Medical Center, Morristown, New Jersey ALACHUA, Fla., Oct. 05, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology [...]
XBiotech Announces Enrollment Completion in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Atopic Dermatitis
05/10/2018
AUSTIN, Texas, Oct. 05, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of [...]
Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program
05/10/2018
NEW HAVEN, Conn., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]
Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program
05/10/2018
SOUTH SAN FRANCISCO, Calif., and TOKYO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their [...]
BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida
05/10/2018
ANAHEIM, CA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today [...]
Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
05/10/2018
-PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease - -Study data highlights the strong positive [...]
Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day
05/10/2018
-Updated response rate of 50% in advanced renal carcinoma treated with CB-839 + cabozantinib -CB-839 clinical trial collaboration with Pfizer -Presentation of INCB001158 data expected in 1H2019 -R&D day hosted today [...]

Pages